Alemtuzumab
Alemtuzumab is a pharmaceutical drug with 186 clinical trials. Currently 33 active trials ongoing. Historical success rate of 72.5%.
Success Metrics
Based on 95 completed trials
Phase Distribution
Phase Distribution
53
Early Stage
100
Mid Stage
20
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.9%
95 of 134 finished
29.1%
39 ended early
33
trials recruiting
186
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Belatacept Early Steroid Withdrawal Trial
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Clinical Trials (186)
Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Belatacept Early Steroid Withdrawal Trial
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Allo HSCT for High Risk Hemoglobinopathies
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Haploidentical PBMC Transplant for Severe Congenital Anemias
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Treatment of Familiar Lymphohistiocytosis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 186